Corcept Therapeutics | CORT - Sales Revenues


Corcept Therapeutics reported $164.9M in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 268.06M 15.94M Mar/2026
Alaunos Therapeutics USD 2K 2K Mar/2025
ANI Pharmaceuticals USD 237.5M 9.56M Mar/2026
Ardelyx USD 94.47M 30.74M Mar/2026
Assertio Holdings USD 29.2M 1.92M Sep/2024
Aurora Cannabis CAD 94.19M 3.82M Dec/2025
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Canopy Growth CAD 74.54M 7.86M Dec/2025
Corcept Therapeutics USD 164.9M 37.22M Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
J&J USD 24.1B 500M Mar/2026
Knight Therapeutics CAD 133.11M 11.56M Dec/2025
Lexicon Pharmaceuticals USD 5.49M 8.69M Dec/2025
Merck USD 16.29B 110M Mar/2026
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Novartis USD 13.11B 226M Mar/2026
Novartis USD 13.11B 750M Mar/2026
Pacira USD 177M 19.87M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Supernus Pharmaceuticals USD 207.71M 3.89M Mar/2026
TG Therapeutics USD 194.8M 2.23M Mar/2026